Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Lempp FA"" wg kryterium: Autor


Tytuł:
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.
Autorzy:
Lempp FA; Vir Biotechnology, San Francisco, California 94158, USA. Electronic address: .
Volz T; Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems and Heidelberg Sites, Germany.
Cameroni E; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Benigni F; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Zhou J; Vir Biotechnology, San Francisco, California 94158, USA.
Rosen LE; Vir Biotechnology, San Francisco, California 94158, USA.
Noack J; Vir Biotechnology, San Francisco, California 94158, USA.
Zatta F; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Kaiser H; Vir Biotechnology, San Francisco, California 94158, USA.
Bianchi S; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Lombardo G; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Jaconi S; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Vincenzetti L; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Imam H; Vir Biotechnology, San Francisco, California 94158, USA.
Soriaga LB; Vir Biotechnology, San Francisco, California 94158, USA.
Passini N; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Belnap DM; School of Biological Sciences and Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112, USA.
Schulze A; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Lütgehetmann M; German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems and Heidelberg Sites, Germany; Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Telenti A; Vir Biotechnology, San Francisco, California 94158, USA.
Cathcart AL; Vir Biotechnology, San Francisco, California 94158, USA.
Snell G; Vir Biotechnology, San Francisco, California 94158, USA.
Purcell LA; Vir Biotechnology, San Francisco, California 94158, USA.
Hebner CM; Vir Biotechnology, San Francisco, California 94158, USA.
Urban S; German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems and Heidelberg Sites, Germany; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Dandri M; Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems and Heidelberg Sites, Germany.
Corti D; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Schmid MA; Humabs Biomed SA, A Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: .
Pokaż więcej
Źródło:
Journal of hepatology [J Hepatol] 2023 Nov; Vol. 79 (5), pp. 1129-1138. Date of Electronic Publication: 2023 Jul 17.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
Autorzy:
Gane E; University of Auckland and New Zealand Clinical Research, Auckland, New Zealand. Electronic address: .
Lim YS; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim JB; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Jadhav V; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Shen L; Vir Biotechnology, Inc., San Francisco, California, USA.
Bakardjiev AI; Vir Biotechnology, Inc., San Francisco, California, USA.
Huang SA; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Cathcart AL; Vir Biotechnology, Inc., San Francisco, California, USA.
Lempp FA; Vir Biotechnology, Inc., San Francisco, California, USA.
Janas MM; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Cloutier DJ; Vir Biotechnology, Inc., San Francisco, California, USA.
Kaittanis C; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Sepp-Lorenzino L; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Hinkle G; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Taubel J; Richmond Pharmacology Ltd., St George's University of London, London, UK.
Haslett P; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Milstein S; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Anglero-Rodriguez YI; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Hebner CM; Vir Biotechnology, Inc., San Francisco, California, USA.
Pang PS; Vir Biotechnology, Inc., San Francisco, California, USA.
Yuen MF; Department of Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło:
Journal of hepatology [J Hepatol] 2023 Oct; Vol. 79 (4), pp. 924-932. Date of Electronic Publication: 2023 Jun 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Hepatitis B*/drug therapy
Humans ; Animals ; Mice ; Hepatitis B virus ; Hepatitis B Surface Antigens ; RNAi Therapeutics ; Randomized Controlled Trials as Topic ; Antiviral Agents ; DNA, Viral ; Hepatitis B e Antigens
Czasopismo naukowe
Tytuł:
Neutralization, effector function and immune imprinting of Omicron variants.
Autorzy:
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Piccoli L; Humabs BioMed, Bellinzona, Switzerland.
Case JB; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Beltramello M; Humabs BioMed, Bellinzona, Switzerland.
Guarino B; Humabs BioMed, Bellinzona, Switzerland.
Dang H; Vir Biotechnology, San Francisco, CA, USA.
de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.
Pinto D; Humabs BioMed, Bellinzona, Switzerland.
Sprouse K; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Scheaffer SM; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Bassi J; Humabs BioMed, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs BioMed, Bellinzona, Switzerland.
Muoio F; Humabs BioMed, Bellinzona, Switzerland.
Dini M; Humabs BioMed, Bellinzona, Switzerland.
Vincenzetti L; Humabs BioMed, Bellinzona, Switzerland.
Acosta R; Vir Biotechnology, San Francisco, CA, USA.
Johnson D; Vir Biotechnology, San Francisco, CA, USA.
Subramanian S; Vir Biotechnology, San Francisco, CA, USA.
Saliba C; Humabs BioMed, Bellinzona, Switzerland.
Giurdanella M; Humabs BioMed, Bellinzona, Switzerland.
Lombardo G; Humabs BioMed, Bellinzona, Switzerland.
Leoni G; Humabs BioMed, Bellinzona, Switzerland.
Culap K; Humabs BioMed, Bellinzona, Switzerland.
McAlister C; Vir Biotechnology, San Francisco, CA, USA.
Rajesh A; Vir Biotechnology, San Francisco, CA, USA.
Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Farhat N; Vir Biotechnology, San Francisco, CA, USA.
Bohan D; Vir Biotechnology, San Francisco, CA, USA.
Noack J; Vir Biotechnology, San Francisco, CA, USA.
Chen A; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Quispe J; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.
Larrous F; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.
Cameroni E; Humabs BioMed, Bellinzona, Switzerland.
Whitener B; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Cippà P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Franzetti-Pellanda A; Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Biggiogero M; Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Zappi S; Division of Nephrology, Cantonal Hospital Aarau, Aarau, Switzerland.
Bernasconi L; Institute of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland.
Kim MJ; Division of Nephrology, Cantonal Hospital Aarau, Aarau, Switzerland.
Rosen LE; Vir Biotechnology, San Francisco, CA, USA.
Schnell G; Vir Biotechnology, San Francisco, CA, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA.
Benigni F; Humabs BioMed, Bellinzona, Switzerland.
Franko N; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Yoshiyama C; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Chu H; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.
Schmid MA; Humabs BioMed, Bellinzona, Switzerland.
Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Lanzavecchia A; Humabs BioMed, Bellinzona, Switzerland.
Diamond MS; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA. .; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA. .; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. .; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St Louis, MO, USA. .; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St Louis, MO, USA. .
Corti D; Humabs BioMed, Bellinzona, Switzerland. .
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. .; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA. .
Pokaż więcej
Źródło:
Nature [Nature] 2023 Sep; Vol. 621 (7979), pp. 592-601. Date of Electronic Publication: 2023 Aug 30.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Neutralizing*/chemistry
Antibodies, Neutralizing*/immunology
COVID-19*/immunology
COVID-19*/prevention & control
COVID-19*/virology
SARS-CoV-2*/classification
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Animals ; Cricetinae ; Humans ; Mice ; Angiotensin-Converting Enzyme 2/immunology ; Angiotensin-Converting Enzyme 2/metabolism ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/immunology ; Cross Reactions ; Immune Evasion ; Membrane Fusion ; Neutralization Tests ; Mutation ; Memory B Cells/immunology ; COVID-19 Vaccines/immunology
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Autorzy:
Wedemeyer H; Department of Gastroenterology, Hepatology, and Endocrinology, Cluster of Excellence RESIST (EXC 2155), Hannover, Germany; Hannover Medical School, Hannover, Germany; German Center for Infection Research (DZIF) partner site, Hannover-Braunschweig, Braunschweig, Germany. Electronic address: .
Schöneweis K; MYR GmbH, Bad Homburg, Germany; Department of Infectious Diseases and Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany.
Bogomolov P; Hepatology Department, Moscow Regional Scientific Research, Clinic Institute MF Vladimirsky, Moscow, Russia.
Blank A; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany.
Voronkova N; H-Clinic, Moscow, Russia.
Stepanova T; Modern Medicine Clinic, Moscow, Russia.
Sagalova O; Clinic of the South-Ural State Medical University, Chelyabinsk, Russia.
Chulanov V; Reference Centre for Viral Hepatitis, Central Research Institute of Epidemiology, Moscow, Russia.
Osipenko M; Novosibirsk State Medical University, Novosibirsk, Russia.
Morozov V; Medical Company Hepatology, Samara, Russia.
Geyvandova N; Stavropol State Medical University, Stavropol Regional Clinical Hospital, Stavropol, Russia.
Sleptsova S; Department of Infectious Diseases, Physiology, Dermatology, and Venereology, Medical Institute of the North-Eastern Federal University MK Ammosov, Yakutsk, Russia.
Bakulin IG; Gastroenterology and Dietology SM Riss, North-Western State Medical University, Mechnikov, Russia.
Khaertynova I; Republican Clinical Infectious Diseases Hospital Professor AF Agafonov, Kazan, Russia.
Rusanova M; Infectious Clinical Hospital Number 1, Moscow City Department, Moscow, Russia.
Pathil A; Department of Internal Medicine I, Goethe University Hospital Frankfurt, Frankfurt, Germany.
Merle U; Internal Medicine IV Gastroenterology, Heidelberg University Hospital, Heidelberg, Germany.
Bremer B; Hannover Medical School, Hannover, Germany.
Allweiss L; University Hospital Hamburg-Eppendorf, Centre for Internal Medicine, Medical Clinic and Polyclinic, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lübeck-Borstel-Riems, Germany.
Lempp FA; Department of Infectious Diseases and Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany.
Port K; Hannover Medical School, Hannover, Germany.
Haag M; Clinical Pharmacology, Dr Margarete Fischer-Bosch-Institute, Stuttgart, Germany; University of Tuübingen, Tuübingen, Germany.
Schwab M; Clinical Pharmacology, Dr Margarete Fischer-Bosch-Institute, Stuttgart, Germany; Departments of Clinical Pharmacology, Biochemistry, and Pharmacy, University Hospital Tübingen, Tübingen, Germany.
Zur Wiesch JS; University Hospital Hamburg-Eppendorf, Centre for Internal Medicine, Medical Clinic and Polyclinic, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lübeck-Borstel-Riems, Germany.
Cornberg M; Hannover Medical School, Hannover, Germany.
Haefeli WE; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany.
Dandri M; University Hospital Hamburg-Eppendorf, Centre for Internal Medicine, Medical Clinic and Polyclinic, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lübeck-Borstel-Riems, Germany.
Alexandrov A; MYR GmbH, Bad Homburg, Germany.
Urban S; Department of Infectious Diseases and Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany. Electronic address: .
Pokaż więcej
Źródło:
The Lancet. Infectious diseases [Lancet Infect Dis] 2023 Jan; Vol. 23 (1), pp. 117-129. Date of Electronic Publication: 2022 Sep 13.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis D, Chronic*/drug therapy
Coinfection*/drug therapy
Hepatitis D*/drug therapy
Hepatitis B, Chronic*/drug therapy
Adult ; Humans ; Tenofovir ; Hepatitis B virus ; Hepatitis Delta Virus/genetics ; Adenine/adverse effects ; Antiviral Agents/adverse effects ; RNA ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Autorzy:
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pinto D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
De Marco A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zatta F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bassi J; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Giurdanella M; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Saliba C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Guarino B; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Schmid MA; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Dang HV; Vir Biotechnology, San Francisco, CA, USA.
Hauser K; Vir Biotechnology, San Francisco, CA, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Rivera W; Vir Biotechnology, San Francisco, CA, USA.
Schnell G; Vir Biotechnology, San Francisco, CA, USA.
Rajesh A; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Farhat N; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Noack J; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Janer J; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Soriaga L; Vir Biotechnology, San Francisco, CA, USA.
Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Lanzavecchia A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Piccoli L; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Pizzuto MS; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Corti D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Nov 11; Vol. 378 (6620), pp. 619-627. Date of Electronic Publication: 2022 Oct 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
Antibody Formation*
COVID-19*/immunology
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*
Immune Evasion*
Humans ; Neutralization Tests ; Immunologic Memory ; Memory B Cells/immunology
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread.
Autorzy:
Zhang Z; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Ni Y; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Lempp FA; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Walter L; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Mutz P; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany; Division of Virus-Associated Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bartenschlager R; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany; German Center for Infection Research (DZIF) - Heidelberg Partner Site, Heidelberg, Germany; Division of Virus-Associated Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Urban S; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany; German Center for Infection Research (DZIF) - Heidelberg Partner Site, Heidelberg, Germany. Electronic address: .
Pokaż więcej
Źródło:
Journal of hepatology [J Hepatol] 2022 Oct; Vol. 77 (4), pp. 957-966. Date of Electronic Publication: 2022 May 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis D*/drug therapy
Hepatitis Delta Virus*/genetics
Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Cell Division ; Hepatitis B virus/genetics ; Humans ; Interferon-alpha/pharmacology ; Interferons ; RNA ; Virus Replication
Czasopismo naukowe
Tytuł:
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.
Autorzy:
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Starr TN; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Joshi A; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Giurdanella M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Noack J; Vir Biotechnology, San Francisco, CA 94158, USA.
Abdelnabi R; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Foo SC; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA.
Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Neyts J; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Bloom JD; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Jan 28; Vol. 375 (6579), pp. 449-454. Date of Electronic Publication: 2022 Jan 06.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiotensin-Converting Enzyme 2/*metabolism
Antibodies, Viral/*immunology
Betacoronavirus/*immunology
Broadly Neutralizing Antibodies/*immunology
COVID-19/*therapy
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Angiotensin-Converting Enzyme 2/chemistry ; Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/metabolism ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Viral/chemistry ; Antibodies, Viral/metabolism ; Antibody Affinity ; Broadly Neutralizing Antibodies/chemistry ; Broadly Neutralizing Antibodies/metabolism ; Broadly Neutralizing Antibodies/therapeutic use ; COVID-19/immunology ; Cross Reactions ; Cryoelectron Microscopy ; Epitopes ; Humans ; Immune Evasion ; Mesocricetus ; Models, Molecular ; Molecular Mimicry ; Mutation ; Protein Conformation ; Protein Domains ; Receptors, Coronavirus/chemistry ; Receptors, Coronavirus/metabolism ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection.
Autorzy:
Lempp FA; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Centre for Infection Research (DZIF), 69120 Heidelberg, Germany.
Roggenbach I; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Nkongolo S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Centre for Infection Research (DZIF), 69120 Heidelberg, Germany.; Toronto Centre for Liver Disease, University Health Network, Toronto, ON M5G 1L7, Canada.
Sakin V; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Schlund F; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Schnitzler P; Department of Infectious Diseases, Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Wedemeyer H; Clinic for Gastroenterology and Hepatology, University Hospital Essen, 45147 Essen, Germany.
Le Gal F; Laboratoire de Microbiologie Clinique, Hôpital Avicenne, APHP, 93000 Bobigny, France.
Gordien E; Laboratoire de Microbiologie Clinique, Hôpital Avicenne, APHP, 93000 Bobigny, France.
Yurdaydin C; Department of Gastroenterology, University of Ankara, Ankara 06560, Turkey.; Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul 34450, Turkey.
Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Centre for Infection Research (DZIF), 69120 Heidelberg, Germany.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Nov 26; Vol. 13 (12). Date of Electronic Publication: 2021 Nov 26.
Typ publikacji:
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Point-of-Care Testing*
Antibodies, Viral/*blood
Hepatitis D/*diagnosis
Hepatitis D, Chronic/*diagnosis
Hepatitis Delta Virus/*immunology
Hepatitis delta Antigens/*immunology
Cohort Studies ; Enzyme-Linked Immunosorbent Assay ; Genotype ; Hepatitis D/virology ; Hepatitis D, Chronic/virology ; Hepatitis Delta Virus/genetics ; Hepatitis Delta Virus/isolation & purification ; Humans ; Prevalence ; Recombinant Proteins ; Sensitivity and Specificity ; Serologic Tests ; Time Factors
Czasopismo naukowe
Tytuł:
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies.
Autorzy:
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Soriaga LB; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Noack J; Vir Biotechnology, San Francisco, CA, USA.
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Joshi A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Agostini M; Vir Biotechnology, San Francisco, CA, USA.
Meury M; Vir Biotechnology, San Francisco, CA, USA.
Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA.
Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Martinez-Picado J; IrsiCaixa AIDS Research Institute, Badalona, Spain.; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
Vergara-Alert J; IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, Bellaterra (Cerdanyola del Vallès), Spain.
Izquierdo-Useros N; IrsiCaixa AIDS Research Institute, Badalona, Spain.; Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Purcell LA; Vir Biotechnology, St Louis, MO, USA.
Telenti A; Vir Biotechnology, San Francisco, CA, USA. .
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2021 Oct; Vol. 598 (7880), pp. 342-347. Date of Electronic Publication: 2021 Aug 31.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing/*immunology
Lectins/*metabolism
SARS-CoV-2/*metabolism
SARS-CoV-2/*pathogenicity
Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Cell Adhesion Molecules/metabolism ; Cell Fusion ; Cell Line ; Cricetinae ; Female ; Humans ; Lectins/immunology ; Lectins, C-Type/metabolism ; Membrane Fusion ; Receptors, Cell Surface/metabolism ; SARS-CoV-2/immunology ; Sialic Acid Binding Ig-like Lectin 1/metabolism ; Spike Glycoprotein, Coronavirus/immunology ; Spike Glycoprotein, Coronavirus/metabolism
Czasopismo naukowe
Tytuł:
HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection.
Autorzy:
Roggenbach I; Department of Hepatology, First Hospital of Jilin University, Changchun 130021, China.; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Chi X; Department of Hepatology, First Hospital of Jilin University, Changchun 130021, China.; Phase I Clinical Trials Unit, First Hospital of Jilin University, Changchun 130021, China.
Lempp FA; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Qu B; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Walter L; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Wu R; Department of Hepatology, First Hospital of Jilin University, Changchun 130021, China.
Gao X; Department of Hepatology, First Hospital of Jilin University, Changchun 130021, China.
Schnitzler P; Department of Infectious Diseases, Virology, University Hospital, 69120 Heidelberg, Germany.
Ding Y; Phase I Clinical Trials Unit, First Hospital of Jilin University, Changchun 130021, China.
Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Niu J; Department of Hepatology, First Hospital of Jilin University, Changchun 130021, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Sep 10; Vol. 13 (9). Date of Electronic Publication: 2021 Sep 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepacivirus/*immunology
Hepatitis B Surface Antigens/*blood
Hepatitis C/*epidemiology
Hepatitis C Antibodies/*blood
Hepatitis D/*epidemiology
Hepatitis D/*immunology
Hepatitis Delta Virus/*immunology
China/epidemiology ; Coinfection/epidemiology ; Coinfection/virology ; Germany/epidemiology ; Hepatitis Antibodies/blood ; Hepatitis B virus/immunology ; Humans ; RNA, Viral/blood ; Retrospective Studies ; Seroepidemiologic Studies
Czasopismo naukowe
Tytuł:
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Autorzy:
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Sauer MM; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA.
Low JS; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Housley MP; Vir Biotechnology, San Francisco, CA 94158, USA.
Noack J; Vir Biotechnology, San Francisco, CA 94158, USA.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA.
Jerak J; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA.
Islam S; Vir Biotechnology, San Francisco, CA 94158, USA.
Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Foo C; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Coelmont L; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Marzi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Cassotta A; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Ceschi A; Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Cippà PE; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Faculty of Medicine, University of Zurich, 8057 Zurich, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Ceruti S; Intensive Care Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
Riva A; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.
Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Smithey M; Vir Biotechnology, San Francisco, CA 94158, USA.
Hong D; Vir Biotechnology, San Francisco, CA 94158, USA.
Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA.
Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA.
Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; UT Southwestern Medical Center, Dallas, TX 75390, USA.; Washington University School of Medicine, St. Louis, MO 63110, USA.
Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Sep 03; Vol. 373 (6559), pp. 1109-1116. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Virus Internalization*
Antibodies, Monoclonal/*immunology
Antibodies, Neutralizing/*immunology
Betacoronavirus/*immunology
Spike Glycoprotein, Coronavirus/*chemistry
Spike Glycoprotein, Coronavirus/*immunology
Viral Vaccines/*immunology
Animals ; Antibodies, Monoclonal/isolation & purification ; Antibodies, Neutralizing/isolation & purification ; Convalescence ; Cricetinae ; Cross Reactions ; Humans ; Immunoglobulin Fab Fragments/immunology ; Immunoglobulin Fc Fragments/immunology ; Jurkat Cells ; Lung/immunology ; Membrane Fusion/immunology ; Neutralization Tests ; Peptide Mapping ; Protein Conformation, alpha-Helical ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/genetics ; Viral Load/immunology
Czasopismo naukowe
Tytuł:
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Autorzy:
Starr TN; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Addetia A; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Hernandez P; Vir Biotechnology, San Francisco, CA, USA.
Greaney AJ; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Genome Sciences, University of Washington, Seattle, WA, USA.
Marzi R; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Glass WG; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zhang I; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
Dingens AS; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Wojcechowskyj JA; Vir Biotechnology, San Francisco, CA, USA.
De Marco A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Rosen LE; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Dillen JR; Vir Biotechnology, San Francisco, CA, USA.
Tucker H; Vir Biotechnology, San Francisco, CA, USA.
Bassi J; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Housley MP; Vir Biotechnology, San Francisco, CA, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Lombardo G; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Agostini M; Vir Biotechnology, San Francisco, CA, USA.
Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Culap K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Meury M; Vir Biotechnology, San Francisco, CA, USA.
Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA.
Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
Cameroni E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Stumpf S; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
Croll TI; Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK.
Nix JC; Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Havenar-Daughton C; Vir Biotechnology, San Francisco, CA, USA.
Piccoli L; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
Telenti A; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Pizzuto MS; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chodera JD; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hebner CM; Vir Biotechnology, San Francisco, CA, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Corti D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Bloom JD; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. .; Department of Genome Sciences, University of Washington, Seattle, WA, USA. .; Howard Hughes Medical Institute, Seattle, WA, USA. .
Snell G; Vir Biotechnology, San Francisco, CA, USA. .
Pokaż więcej
Źródło:
Nature [Nature] 2021 Sep; Vol. 597 (7874), pp. 97-102. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Immune Evasion*/genetics
Immune Evasion*/immunology
Broadly Neutralizing Antibodies/*immunology
COVID-19/*virology
Cross Reactions/*immunology
SARS-CoV-2/*classification
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*chemistry
Spike Glycoprotein, Coronavirus/*immunology
Adult ; Aged ; Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/immunology ; Antibodies, Viral/chemistry ; Antibodies, Viral/immunology ; Antibody Affinity ; Broadly Neutralizing Antibodies/chemistry ; COVID-19/immunology ; COVID-19 Vaccines/chemistry ; COVID-19 Vaccines/immunology ; Cell Line ; Cricetinae ; Epitopes, B-Lymphocyte/chemistry ; Epitopes, B-Lymphocyte/genetics ; Epitopes, B-Lymphocyte/immunology ; Female ; Humans ; Male ; Mesocricetus ; Middle Aged ; Models, Molecular ; SARS-CoV-2/chemistry ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/genetics ; Vaccinology ; COVID-19 Drug Treatment
Czasopismo naukowe
Tytuł:
Broad sarbecovirus neutralization by a human monoclonal antibody.
Autorzy:
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA.
Starr TN; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Marzi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Wang Z; Department of Biochemistry, University of Washington, Seattle, WA, USA.
De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Housley MP; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Rosen LE; Vir Biotechnology, San Francisco, CA, USA.
Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Addetia A; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Guarino B; Vir Biotechnology, San Francisco, CA, USA.
Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Saliba C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Giacchetto-Sasselli I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
Havenar-Daughton C; Vir Biotechnology, San Francisco, CA, USA.
Schmid MA; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
Telenti A; Vir Biotechnology, San Francisco, CA, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Bloom JD; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Howard Hughes Medical Institute, Seattle, WA, USA.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. .
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2021 Sep; Vol. 597 (7874), pp. 103-108. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Antibodies, Monoclonal/*immunology
Antibodies, Monoclonal/*therapeutic use
Antibodies, Viral/*immunology
Broadly Neutralizing Antibodies/*immunology
Broadly Neutralizing Antibodies/*therapeutic use
COVID-19/*prevention & control
SARS-CoV-2/*classification
SARS-CoV-2/*immunology
Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Viral/chemistry ; Antibodies, Viral/therapeutic use ; Broadly Neutralizing Antibodies/chemistry ; COVID-19/immunology ; COVID-19/virology ; Cross Reactions/immunology ; Disease Models, Animal ; Female ; Humans ; Immune Evasion/genetics ; Immune Evasion/immunology ; Mesocricetus/immunology ; Mesocricetus/virology ; Mutation ; Neutralization Tests ; SARS-CoV-2/chemistry ; SARS-CoV-2/genetics ; Viral Zoonoses/immunology ; Viral Zoonoses/prevention & control ; Viral Zoonoses/virology
Czasopismo naukowe
Tytuł:
Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.
Autorzy:
Wang W; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany. Electronic address: .
Lempp FA; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany.
Schlund F; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Walter L; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Decker CC; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Zhang Z; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Ni Y; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany.
Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany. Electronic address: .
Pokaż więcej
Źródło:
Journal of hepatology [J Hepatol] 2021 Aug; Vol. 75 (2), pp. 311-323. Date of Electronic Publication: 2021 May 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Genotype*
Hepatitis B virus/*enzymology
Hepatitis Delta Virus/*genetics
Hepatitis B virus/pathogenicity ; Hepatitis Delta Virus/immunology ; Humans
Czasopismo naukowe
Tytuł:
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
Autorzy:
McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Chen A; Vir Biotechnology, San Francisco, CA 94158, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Zepeda S; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA 94158, USA.
Zhou J; Vir Biotechnology, San Francisco, CA 94158, USA.
Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA.
Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, 3000 Leuven, Belgium.
Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, 3000 Leuven, Belgium.
Rothlauf PW; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Bloyet LM; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, 3000 Leuven, Belgium.
Riva A; III Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, 20157 Milan, Italy.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: .
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: .
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Electronic address: .
Pokaż więcej
Źródło:
Cell [Cell] 2021 Apr 29; Vol. 184 (9), pp. 2332-2347.e16. Date of Electronic Publication: 2021 Mar 16.
Typ publikacji:
Journal Article
MeSH Terms:
Antigens, Viral/*immunology
SARS-CoV-2/*immunology
Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/immunology ; Antibodies, Neutralizing/immunology ; COVID-19/immunology ; COVID-19/virology ; Cricetinae ; Epitope Mapping ; Genetic Variation ; Models, Molecular ; Mutation/genetics ; Neutralization Tests ; Protein Domains ; RNA, Viral/genetics ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/ultrastructure
Czasopismo naukowe
Tytuł:
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
Autorzy:
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA.
Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Dang HV; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA.
McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Bowen J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Minola A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
De Marco A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Guarino B; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bianchi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Lauron EJ; Vir Biotechnology, San Francisco, CA 94158, USA.
Tucker H; Vir Biotechnology, San Francisco, CA 94158, USA.
Zhou J; Vir Biotechnology, San Francisco, CA 94158, USA.
Peter A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA.
Wojcechowskyj JA; Vir Biotechnology, San Francisco, CA 94158, USA.
Case JB; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Chen RE; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA 94158, USA.
Meury M; Vir Biotechnology, San Francisco, CA 94158, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA.
Spreafico R; Vir Biotechnology, San Francisco, CA 94158, USA.
Dillen J; Vir Biotechnology, San Francisco, CA 94158, USA.
Ng C; Vir Biotechnology, San Francisco, CA 94158, USA.
Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Culap K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Schmid MA; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Cameroni E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Riva A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.
Gabrieli A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.
Galli M; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.
Pizzuto MS; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Diamond MS; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; Washington University School of Medicine, St. Louis, MO, USA.; UTSouthwestern Medical Center, Dallas, TX, USA.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Corti D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Fink K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. .
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2020 Nov 20; Vol. 370 (6519), pp. 950-957. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
Betacoronavirus/*immunology
Coronavirus Infections/*prevention & control
Pandemics/*prevention & control
Peptidyl-Dipeptidase A/*immunology
Pneumonia, Viral/*prevention & control
Spike Glycoprotein, Coronavirus/*antagonists & inhibitors
Amino Acid Motifs/immunology ; Angiotensin-Converting Enzyme 2 ; Animals ; Antibodies, Neutralizing/administration & dosage ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/administration & dosage ; Antibodies, Viral/isolation & purification ; CHO Cells ; COVID-19 ; Coronavirus Infections/therapy ; Cricetinae ; Cricetulus ; Cryoelectron Microscopy ; HEK293 Cells ; Humans ; Immunodominant Epitopes/chemistry ; Immunodominant Epitopes/immunology ; Microscopy, Electron ; Pneumonia, Viral/therapy ; Protein Domains/immunology ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł:
The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA.
Autorzy:
Nkongolo S; University Hospital Heidelberg (Germany), Center for Infectious Diseases, Molecular Virology, Germany; German Center for Infection Research (DZIF), Partner Site Heidelberg, TTU Hepatitis, Germany. Electronic address: .
Nußbaum L; University Hospital Heidelberg (Germany), Center for Infectious Diseases, Molecular Virology, Germany. Electronic address: .
Lempp FA; University Hospital Heidelberg (Germany), Center for Infectious Diseases, Molecular Virology, Germany; German Center for Infection Research (DZIF), Partner Site Heidelberg, TTU Hepatitis, Germany. Electronic address: .
Wodrich H; Laboratoire de Microbiologie Fondamentale et Pathogénicité, University of Bordeaux, France. Electronic address: .
Urban S; University Hospital Heidelberg (Germany), Center for Infectious Diseases, Molecular Virology, Germany; German Center for Infection Research (DZIF), Partner Site Heidelberg, TTU Hepatitis, Germany. Electronic address: .
Ni Y; University Hospital Heidelberg (Germany), Center for Infectious Diseases, Molecular Virology, Germany; German Center for Infection Research (DZIF), Partner Site Heidelberg, TTU Hepatitis, Germany. Electronic address: .
Pokaż więcej
Źródło:
Antiviral research [Antiviral Res] 2019 Aug; Vol. 168, pp. 146-155. Date of Electronic Publication: 2019 Apr 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents/*pharmacology
Benzoates/*pharmacology
DNA, Circular/*genetics
Hepatitis B virus/*drug effects
Receptors, Retinoic Acid/*agonists
Tetrahydronaphthalenes/*pharmacology
Transcription, Genetic/*drug effects
Acitretin/pharmacology ; Cells, Cultured ; DNA, Viral/genetics ; Hepatitis B Surface Antigens/metabolism ; Hepatitis B e Antigens/metabolism ; Hepatitis Delta Virus/drug effects ; Hepatocytes/drug effects ; Hepatocytes/virology ; Humans ; RNA, Viral/metabolism
Czasopismo naukowe
Tytuł:
Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus.
Autorzy:
Ni Y; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.; German Center for Infection Research (DZIF), partner site Heidelberg, TTU Hepatitis, Heidelberg, Germany.
Zhang Z; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Engelskircher L; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Verch G; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Tu T; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Lempp FA; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.; German Center for Infection Research (DZIF), partner site Heidelberg, TTU Hepatitis, Heidelberg, Germany.
Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany. .; German Center for Infection Research (DZIF), partner site Heidelberg, TTU Hepatitis, Heidelberg, Germany. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Jul 10; Vol. 9 (1), pp. 10021. Date of Electronic Publication: 2019 Jul 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis Delta Virus/*physiology
Hepatocytes/*virology
Virus Cultivation/*methods
Cell Line ; Coculture Techniques ; Hep G2 Cells ; Hepatocytes/cytology ; Hepatocytes/metabolism ; Humans ; Viral Load ; Virus Internalization ; Virus Replication
Czasopismo naukowe
Tytuł:
Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation.
Autorzy:
Lempp FA; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany.; German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, 69120, Germany.
Schlund F; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Rieble L; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Nussbaum L; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Link C; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Zhang Z; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany.
Ni Y; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany.; German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, 69120, Germany.
Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, 69120, Germany. .; German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, 69120, Germany. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2019 May 22; Vol. 10 (1), pp. 2265. Date of Electronic Publication: 2019 May 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents/*pharmacology
Hepatitis Delta Virus/*drug effects
Viral Envelope Proteins/*metabolism
Virus Replication/*drug effects
Drug Evaluation, Preclinical/methods ; Hep G2 Cells ; Hepatitis B virus/metabolism ; Hepatitis Delta Virus/physiology ; Hepatitis delta Antigens/metabolism ; Humans ; Immunity, Innate/drug effects ; Inhibitory Concentration 50
Czasopismo naukowe
Tytuł:
Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.
Autorzy:
Lempp FA; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.; German Centre for Infection Research, partner site Heidelberg, Heidelberg, Germany.
Wiedtke E; Cluster of Excellence CellNetworks, Department of Infectious Diseases, Virology, BioQuant, University Hospital Heidelberg, Heidelberg, Germany.
Qu B; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Roques P; Division of ImmunoVirology, Institute of Emerging Diseases and Innovative Therapies, Centre d'Energie Atomique, Fontenay aux Roses, Paris, France.; UMRE01, UMR1184, Université Paris Sud, Orsay, France.
Chemin I; Université de Lyon, INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Vondran FWR; Regenerative Medicine and Experimental Surgery, Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany.; German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Hannover, Germany.
Le Grand R; Division of ImmunoVirology, Institute of Emerging Diseases and Innovative Therapies, Centre d'Energie Atomique, Fontenay aux Roses, Paris, France.; UMRE01, UMR1184, Université Paris Sud, Orsay, France.
Grimm D; Cluster of Excellence CellNetworks, Department of Infectious Diseases, Virology, BioQuant, University Hospital Heidelberg, Heidelberg, Germany.
Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.; German Centre for Infection Research, partner site Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło:
Hepatology (Baltimore, Md.) [Hepatology] 2017 Sep; Vol. 66 (3), pp. 703-716. Date of Electronic Publication: 2017 Jul 18.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression Regulation, Viral*
Hepatitis B virus/*genetics
Host Factor 1 Protein/*metabolism
Organic Anion Transporters, Sodium-Dependent/*genetics
Symporters/*genetics
Taurocholic Acid/*metabolism
Virus Replication/*genetics
Animals ; Cells, Cultured ; Disease Models, Animal ; Dogs ; Hepatitis B/genetics ; Hepatitis B/physiopathology ; Hepatocytes/metabolism ; Hepatocytes/virology ; Macaca mulatta ; Mice ; Mice, Inbred C57BL ; Random Allocation ; Rats ; Rats, Wistar ; Receptors, Virus/metabolism ; Signal Transduction ; Species Specificity ; Swine ; Transfection
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies